$10.0M
1 filing since 2025 · latest Other filed
Holobiome is a Boston-based microbiome platform biotechnology company founded in 2018 by research scientists from Northeastern University. It translates human gut microbiome science into next-generation probiotics and targeted therapeutics, with an initial focus on mapping and manipulating the gut-brain axis. The company maintains the Microbiome Vault, a growing strain collection aiming to be a comprehensive library of human gut bacteria, and its lead asset is a next-generation probiotic targeting biology relevant to depression. It has been backed by venture investors, NIH grants, and corporate partnerships including Unilever and Johnson & Johnson Consumer.
What sets it apart
The Microbiome Vault strain bank plus deep expertise in cultivating previously unculturable gut bacteria lets Holobiome screen the microbiome for target activity, an approach that produced a lead gut-brain probiotic showing antidepressant-comparable effects in animal models.
A microbiome discovery platform built on a continuously growing strain collection of human gut bacteria, international sample collection, and screening assays that make the microbiome searchable for target biological activity.
